Dualsystems Biotech

Executive Summary

Dualsystems Biotech AG is a Swiss biotechnology company founded in 2006 that specializes in mapping protein-protein interactions on living cells. Its proprietary LRC-TriCEPS and HATRIC-LRC platforms enable high-specificity target and off-target identification for extracellular ligands without the need for genetic modification, applicable to any cell type including primary cells and tissues. As a service provider, the company supports both academic and industry clients in custom proteomics, positioning itself as a key enabler in drug discovery and development. With a strong intellectual property portfolio and a focus on undruggable targets, Dualsystems addresses a critical gap in early-stage target identification, potentially reducing attrition rates in clinical development. The company has generated significant traction through collaborations and service contracts, though it remains in the pre-clinical stage without disclosed financing rounds. Its technology has been validated in peer-reviewed publications and is increasingly adopted for complex target discovery in oncology, immunology, and neurodegenerative diseases. Given its niche in the proteomics services market and the growing demand for precision medicine tools, Dualsystems is well-positioned for growth. However, its reliance on service revenue and lack of internal pipeline create dependence on external partnerships for scalability and validation.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a Major Pharma Partnership for LRC-TriCEPS Platform60% success
• Q4 2026Publication of Validation Data for HATRIC-LRC in Primary Cells75% success
• Q2 2027Series A Funding Round or Grant Award for Platform Expansion50% success